Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
about
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worsePhase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experienceEarly mortality and overall survival in oncology phase I trial participants: can we improve patient selection?Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study.A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unitBody composition, symptoms, and survival in advanced cancer patients referred to a phase I serviceSurvival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experienceParticipation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experienceSignificance of platelet count in esophageal carcinomasOutcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experiencePhase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience.Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.Early oncology clinical trial design in the era of molecular-targeted agents.Risks and benefits of phase 1 clinical trial participation.Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.Cancer targeting vaccines: surrogate measures of activity.Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Qualitative analysis of clinical research coordinators' role in phase I cancer clinical trials.
P2860
Q33422964-52496EF7-2E51-4FA0-97E4-1349FB00ED73Q33658203-23C34A55-EB87-45F1-82A1-C3913BF97C64Q33899157-EA607D42-C1B1-41F9-B657-D4554B118F92Q34040965-EB431990-8598-4F1C-A5B8-340C81869473Q34115856-D3F262A9-D507-4F59-99AC-DF3516E34634Q34122784-28675A29-FA15-491E-8DD1-F82C95407A0CQ34123648-003F7418-9011-45A7-963F-01FD4D6D86F3Q34252383-5DBD7CE9-7C34-47D6-AD2B-705DF79FC771Q34801461-E9C48A78-E357-4327-993C-94D2ABC83745Q34996025-9AE3408F-7C62-4F89-B7AA-BD53702639E2Q35584482-C7039C6E-BD98-47C3-8AE1-6FBABC26E2C7Q35632548-83C429D3-8C1D-43B5-B242-8625DA054E03Q35680026-EB8E0CC7-0CA0-4200-A04B-F2EDB5930603Q36136045-825DB2A8-2AB9-4A86-9E06-DD0F64AFB7B8Q36136110-0B7F1BEC-5118-4FAD-9874-C6132E311F45Q36288003-A5615700-FC66-4281-A45F-76094E99BDB8Q37107200-FAE18E49-4844-4A90-9769-6B5F1311E7C8Q37444815-36A3C987-8F05-4011-93E1-04318E2CD39BQ37783623-0895CD87-4A45-4A3E-8007-4A30EDC32C28Q38222465-C5AD3AA2-FC53-4742-AE93-369068E4CD59Q38735014-026997E6-BB5B-497D-8CAD-1F6F2A4EFEFBQ39456127-CA88194B-798C-45E2-8C0A-479DAC4CB0AAQ39888234-752AA838-CF00-471F-95A5-631FD852F533Q40368139-540256E8-AA11-4515-BAB5-7085991E7EEAQ40841994-E7ABA74E-5989-4CB1-9C67-724C7117BF16Q41222516-E0855699-A4E8-4D0F-93C8-ECC20784E651Q43455943-BCBC4A33-6E03-4A8F-8607-545365AF7E59Q47990284-1A432A57-FED4-4E79-A275-A4396D2D4CA0Q55399727-ED35E3E8-7699-4210-8112-810C2D30AE80
P2860
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@en
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@nl
type
label
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@en
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@nl
prefLabel
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@en
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@nl
P2093
P50
P356
P1433
P1476
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
@en
P2093
David Hong
Jennifer Wheler
Tiffiny Jackson
P304
P356
10.1002/CNCR.24018
P407
P577
2009-03-01T00:00:00Z